 When Astellas closed its 3 billion buyout of Audentes Therapeutics, the J.P. Morgan conference crowd was full of backhanded congratulations. They offered Natalie Holles, then the newly minted CEO of Audentes, their kudos along with horror stories of biotechs that had been subsumed by Big Pharma and lost their spunk. 